News | April 27, 2022
Syngene full-year revenue from operations up 19% to Rs. 2604 crore
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Key takeaways of recent quarter & conference call highlights
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The drug is being developed at lab scale for the first-line of treatment of Covid-19
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
_256_384.jpg)
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
Domestic business was up 41.9% YoY and 27.7% QoQ
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
Subscribe To Our Newsletter & Stay Updated
